A new panel of U.S. vaccine advisers appointed by Health Secretary Robert F. Kennedy Jr. will vote on flu shots that contain ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

RSV monoclonal antibody, clesrovimab,” which was approved by the FDA yesterday, Leerink Partners LLC analyst Daina Graybosch said. Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial ...

Merck stands to lose $62 billion over four years following the loss of exclusivity on KEYTRUDA, making Moderna's $13 billion market cap a bargain. The worsening Avian Flu crisis adds optionality ...

a division of Merck & Co., Inc., Rahway, New Jersey, USA, announced the US Department of Agriculture (USDA) approval of Nobivac NXT Canine Flu H3N2, a next-level solution to help safeguard dogs ...

akin to a flu vaccine, the shots from Moderna and Pfizer were 95 percent effective in clinical trials. That set a high bar for other vaccines, one that Merck concluded last month it could not meet.

He said the vaccine manufacturer would benefit from Merck’s resources to expand its technology into other areas such as foot-and-mouth-disease in cattle and canine influenza in dogs. Merck also ...